We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
MHRA approves triheptanoin to treat adult and paediatric patients with a group of rare inherited disorders.
Children aged five and over with severe sickle-cell disease and transfusion-dependent β-thalassemia, can now be treated with Casgevy (exagamglogene autotemcel), following an extension of its UK authorisation by the MHRA.
As with any medicine, the MHRA will keep the safety and effectiveness of deuruxolitinib under close review.
The Medicines and Healthcare products Regulatory Agency (MHRA) has set out ambitious plans to translate cutting-edge scientific and technological innovation into better health outcomes for patients across all four nations of…
As with all licensed medicines, the MHRA will keep the safety and effectiveness of catumaxomab under close review.
As with all licensed medicines, the MHRA will keep the safety and effectiveness of lurbinectedin under close review.
As with any medicine, the MHRA will keep the safety and effectiveness of vimseltinib (romvizma) under close review.
As with all GLP-1 receptor agonists, the MHRA will keep the safety and effectiveness of orforglipron under close review.
As with any medicinal product, the MHRA will keep the safety and effectiveness of remibrutinib under close review.
Aficamten is recommended by NICE at the same time it was approved by the MHRA, thanks to improvements driven by closer working between the two organisations.
The new inhalers use a next-generation propellant designed to reduce environmental impact while maintaining the same established treatment.
As with any medicinal product, the MHRA will keep the safety and effectiveness of nerandomilast under close review.
Merkel cell carcinoma (MCC) is a rare and aggressive type of skin cancer that develops from Merkel cells, specialised neuroendocrine cells found in the top layer of the skin.
The semaglutide injection has been approved to treat metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced liver fibrosis.
MHRA CEO argues that for the UK’s long-term health and prosperity, regulation should help lead, rather than follow, innovation
As with any medicinal product, the MHRA will keep the safety and effectiveness of the intravesical delivery system containing gemcitabine under close review.
As with any medicine, the MHRA will keep the safety and effectiveness of the adrenaline nasal spray under close review.
Having met the MHRA’s rigorous standards of safety, quality and effectiveness, the semaglutide tablet has been approved in the UK for weight loss and weight management.
As with all medicines, the MHRA will keep the safety and effectiveness of Nipolcalimab under close review.
The adjuvanted trivalent influenza vaccine works by stimulating the immune system to produce its own protection against flu.
Do not include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).